With oil prices feeding into higher bond yields across major markets, investors are being reminded how quickly macro shocks can ripple through portfolios. In choppier conditions, founder led companies can look appealing because leaders often hold significant stakes and stay focused on long term value creation rather than quarterly targets. This article highlights three stocks from the Founder Led Companies screener that fit that mindset and may interest long term investors.
The stocks covered below are just a starting sample, with the full founder led screen surfacing 84 more companies with equally compelling narratives that are not discussed in this article. To identify and analyze the founder led opportunities that best fit your portfolio, head straight into the Founder-Led Companies screener.
Flight Centre Travel Group (ASX:FLT)
Overview: Flight Centre Travel Group is a global travel retailer that serves both leisure and corporate customers through its Flight Centre brand and a range of specialist brands, offering everything from mass market holidays and youth travel to premium and cruise packages, as well as corporate travel management for organisations of all sizes. It also runs tour operations, hotel and destination management, foreign exchange, travel training, recruitment marketing, bike retailing, and employee benefit services, with operations spanning Australia, New Zealand, the Americas, Europe, the Middle East, Africa, Asia and beyond.
Operations: Flight Centre Travel Group generates most of its revenue from leisure travel at about A$1.45b, followed by corporate travel at about A$1.18b and A$239 million from Global HQ services, with Australia and New Zealand contributing around A$1.53b of revenue.
Market Cap: A$2.76b
Flight Centre Travel Group stands out in this founder led screen because it couples a large global footprint with a clear push into higher margin, tech enabled corporate and premium travel. Ongoing investment in proprietary digital and AI tools, plus recent partnerships with Emburse and Blockskye, point to a business that is trying to modernise how trips are booked, paid for and managed. At the same time, the approved A$200 million buyback signals management confidence in the company’s value. You do need to weigh that against funding risk, an unstable dividend record and pressure in regions like Asia, which could keep margins in check. For patient investors, that tension between transformation and execution risk is what makes Flight Centre worth a closer look.
Flight Centre’s expansion into higher margin corporate and premium travel, supported by digital and AI tools, could be masking a very different risk reward profile than you expect. Get the full picture in the analysis report for Flight Centre Travel Group
Build your own founder-led travel and tech shortlist
Flight Centre Travel Group and the other stocks in this list all surfaced from a single Simply Wall St screen, but the real edge comes when you set your own rules. Use our customisable Screener to mix filters like valuation, balance sheet strength and risks, or jump straight into our curated Investing Ideas for ready made shortlists.
Macquarie Technology Group (ASX:MAQ)
Overview: Macquarie Technology Group runs data centres, cloud, cybersecurity and telecom services for Australian corporate and government customers, providing the digital infrastructure and managed services that keep their networks, data and applications secure and online.
Operations: Macquarie Technology Group generates most of its A$379 million in revenue from Cloud Services & Government at about A$224 million, followed by Telecom at about A$108 million and Data Centres at about A$84 million, all from Australia.
Market Cap: A$1.61b
Macquarie Technology Group is worth a closer look if you are interested in the backbone of Australia’s digital economy, but you also need to be comfortable with trade offs. The company has grown earnings strongly over five years and analysts still expect growth, yet margins are slim, net profit margins have eased to 8.8% and forecast return on equity stays in the mid single digits. All funding comes from external borrowing, which adds another layer of risk. At the same time, a P/E that sits well above peers and a target price more than 20% above the current share price show how much confidence is already priced in. That mix of growth ambition, funding structure and valuation is where the real story lies for investors.
Macquarie Technology Group’s slim 8.8% net margins and mid single digit forecast return on equity could be masking a very different earnings story than the headline growth suggests. See how that trade off looks across the analyst forecasts for Macquarie Technology Group
Mesoblast (ASX:MSB)
Overview: Mesoblast is a Melbourne based biotech that develops mesenchymal cell therapies aimed at treating severe inflammatory and cardiovascular conditions, including steroid refractory acute graft versus host disease, inflammatory bowel disease, chronic heart failure and chronic low back pain.
Operations: Mesoblast currently generates about $65 million in revenue from developing its cell technology platform for commercialization.
Market Cap: A$3.13b
Mesoblast attracts attention because it is already booking Ryoncil sales in pediatric steroid refractory acute GvHD while working on label expansions and late stage trials in much larger markets like chronic low back pain and heart failure. Forecasts point to strong potential revenue and earnings growth, yet the business remains loss making with a high P/S multiple and relies on external funding, so the path to profitability and cash needs matter a lot. Recent debt refinancing and RMAT designations help, but investors still have to weigh clinical, regulatory and reimbursement risk. If the late stage programs and adult indications land as planned, the gap between today’s losses and the long term opportunity could look very different than it does now.
Mesoblast’s progression from current Ryoncil sales into much larger late-stage programs is where the story becomes particularly interesting. See how growth forecasts compare with funding needs in the analyst forecasts for Mesoblast
Seeking Alternatives Beyond Your Current Watchlist
Fresh opportunities can move from under the radar to full momentum faster than many expect. Scan these focused stock ideas before the crowd and consider them early in your research process.
- Identify companies that are building strength while others hesitate and review the curated list of solid balance sheet and fundamentals (19 results) before prices fully reflect that resilience.
- Explore the next phase of AI infrastructure developments by reviewing the 57 AI infrastructure stocks while these potential beneficiaries may still be under the radar.
- Evaluate potential income-oriented stocks before yields change significantly and review the curated 5 dividend fortresses while payout levels appear compelling based on your criteria.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com